Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by Tumbleweed67on Aug 01, 2010 2:11am
597 Views
Post# 17313644

RE: MORE INSIDER ACTION

RE: MORE INSIDER ACTIONInsider name: Brown, Ian Stephen
Insider's Relationship to Issuer: 4 - Director of Issuer
Ceased to be Insider: Not applicable
Security designation: Common Shares

2006-01-09 Direct Ownership :
Opening Balance-Initial SEDI Report                                                                         [119,500 ]

2007-02-01 Direct Ownership :
Acquisition or disposition under a prospectus exemption +125,000     0.20     [244,500 ]

2007-02-20 Direct Ownership :
Acquisition or disposition in the public market                        -47,500      0.63     [197,000]

2007-11-09 Direct Ownership :
Acquisition or disposition under a prospectus                        +75,000     0.35     [272,000]

2010-07-27 Direct Ownership :
Acquisition or disposition in the public market                      -100,000     0.085    [172,000]
Bullboard Posts